Nanollose Taps Andrew Moullin to Accelerate Commercialisation Drive

Leadership Change at a Critical Growth Phase

Nanollose Limited (ASX: NC6), a pioneering biomaterials company, has announced the appointment of Andrew Moullin as Managing Director and Chief Executive Officer, effective 14 July 2025. This strategic leadership change comes at a pivotal moment as Nanollose prepares to transition its innovative microbial cellulose technology from development to commercialisation.

Moullin brings a wealth of experience spanning over two decades in legal, commercial, and corporate leadership roles. His background includes senior positions at Iluka Resources Limited, DLA Piper, Macro Metals, and CLSA, as well as entrepreneurial ventures that culminated in successful business exits and IPO readiness. This blend of legal acumen and commercial savvy positions him well to steer Nanollose through its next growth phase.

Balancing Commercial Focus with Innovation

The appointment is designed to complement the existing leadership structure, with Executive Chairman Dr Wayne Best continuing to lead the company’s research and development efforts. This division of responsibilities allows Moullin to concentrate on commercial strategy, project execution, and investor relations, while Best focuses on technological advancements and new product development.

Dr Best highlighted Moullin’s commercial expertise as a key asset, stating that it underscores Nanollose’s near-term focus on commercialisation and growth. The company’s flagship technology, which produces cellulose fibres from agricultural waste rather than trees, has significant environmental benefits and broad industry applications, particularly in sustainable fashion.

Incentives Aligned with Milestones

Moullin’s remuneration package includes a base salary of $267,000 per annum, with additional short-term incentives tied to performance metrics. Notably, the package features substantial long-term equity incentives comprising performance rights and options, contingent on achieving key commercial milestones such as securing material contracts, offtake agreements, and pilot plant funding.

These incentives align Moullin’s interests with shareholder value creation and underscore the company’s confidence in his ability to unlock commercial opportunities. The vesting conditions also reflect critical steps in Nanollose’s path to market, including product lifecycle assessments and revenue targets.

Looking Ahead

As Nanollose moves beyond laboratory-scale innovation into pilot production, already underway in partnership with Birla Cellulose in India, the leadership transition signals a sharpened focus on scaling and commercial partnerships. Moullin’s track record in complex negotiations and project delivery will be tested as the company seeks to convert its promising technology into sustainable revenue streams.

Investors will be watching closely to see how this new leadership dynamic influences Nanollose’s ability to secure commercial contracts and advance its pilot plant development, both crucial for validating the company’s growth prospects.